The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mesoblast (MSB) has reported a COVID-19 breakthrough using its cell therapy treatment
  • The company saw an 83 per cent survival in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome
  • The trial showed that 75 per cent of the COVID-19 patients had successfully come off ventilator support around 10 days after the treatment
  • In contrast, one New York hospital network only saw a 12 per cent survival rate using the standard of care within the same period Mesoblast treated its patients
  • Mesoblast is up 22.1 per cent on the market this morning, trading for $2.40 per share

Mesoblast (MSB) has reported an 83 per cent survival in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS).

Earlier this month, MSB was approved to trial its novel remestemcel-L treatment for COVID-19 ARDS in the United States.

The company treated 12 people in New York between March and April 2020 using the cell therapy treatment.

The trial showed that 75 per cent ( nine out of 12) of the COVID-19 patients had successfully come off ventilator support at an average of 10 days. Within those days, seven patients were discharged from the hospital.

Patients received a variety of experimental agents prior to using Mesoblasts treatment.

All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at New York City’s Mt Sinai hospital.

In contrast, COVID-19 ventilator-dependent patients at a New York hospital network, receiving the standard care during March and April, saw only nine per cent (38 out of 445 patients) come off ventilator support.

At another major referral hospital network, standard care patients saw an 88 per cent mortality rate and a survival rate of 12 per cent.

Those figures are in line with mortality rates experienced by moderate to severe ARDS patients in China earlier.

Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines.

“The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS,” Chief Executive Dr Silviu Itescu said.

“We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients,” he added.

Mesoblast is up 22.1 per cent on the market this morning, trading for $2.40 per share at 10:32 am AEST.

msb by the numbers
More From The Market Online

Market Close: ASX slides 1.58% as global AI sell-off rattles investors

My nerves, along with my portfolio, have taken a beating over the last couple of weeks – and I’m sick of seeing red!

Market Close: Materials drag ASX lower as seven sectors finish higher

The Australian share market finished lower on Monday, with weakness across the resources sector weighing on the broader market despite gains across most

Market Close: ASX slides as resources and miners lead broad market sell-off

The Australian sharemarket came under renewed pressure on Tuesday 17th Nov, with selling extending across almost every sector as resources and energy

Market Close: ASX slides as technology and materials stocks lead broad market decline

The Australian share market finished lower on Wednesday, with the S&P/ASX 200 falling 0.69% to close at 8,821.80 points.